DiCE Molecules bags $80M in a Series C
The financing will support the progression of DiCE’s IL-17 antagonist into clinical trials
Immunology
Amgen licenses AMG 634 to MDGH
AMG 634, an investigational treatment for tuberculosis and leprosy, has been licensed to Medicines Development for Global Health
Best of Immuno-oncology
Download DDN’s “Best of Immuno-oncology” ebook to learn more about recent research in cancer immunotherapy. This ebook includes stories about antibody approaches for treating cancer, the potential of CAR-T therapies, precision cancer immunotherapy directed by immune-profiling, and cancer neoepitope discovery.
Why cellular context is vital for genomics and transcriptomics insights (Sanger Institute)
Gosia Trynka, Group Leader at The Sanger Institute and Experimental Science Director at Open Targets, talks about the importance of cellular context for translating genomic and transcriptomic insights into actionable targets.
CROs create COVID partnership
U.K companies seek to provide drug discovery and development services despite pandemic restrictions
OSE brings CLEC-1 to AACRR
CLEC-1 is a new therapeutic target for immuno-oncology.
The research program focuses on developing a cancer immunotherapy targeting CLEC-1, a newly identified C-type lectin receptor, to block suppressive functions of myeloid cells and restore antitumor response to T lymphocytes. Suppressive myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T lymphocytes.
IONTAS announces collaboration
Partnership with Inotrem will seek to identify novel immunotherapy targets
DDN Webinar: Synthetic DNA Technologies Enable Fast and Responsive Antibody-based Therapeutics and Diagnostics for SARS-CoV-2
Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry.
A ‘Scenic’ view on cancer treatment
Scenic Biotech awarded €3.1-million from Dutch government to progress CD47/QPCTL immuno-oncology program
